132 related articles for article (PubMed ID: 20932666)
1. Prolongation of total treatment time because of infrequently missed days of treatment is not associated with inferior biochemical outcome after dose-escalated radiation therapy for prostate cancer.
Liauw SL; Liauw SH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):751-7. PubMed ID: 20932666
[TBL] [Abstract][Full Text] [Related]
2. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
Liauw SL; Fricano J; Correa D; Weichselbaum RR; Jani AB
Cancer; 2009 Apr; 115(8):1784-90. PubMed ID: 19208426
[TBL] [Abstract][Full Text] [Related]
3. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
[TBL] [Abstract][Full Text] [Related]
4. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
5. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.
Gutt R; Tonlaar N; Kunnavakkam R; Karrison T; Weichselbaum RR; Liauw SL
J Clin Oncol; 2010 Jun; 28(16):2653-9. PubMed ID: 20421534
[TBL] [Abstract][Full Text] [Related]
6. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
7. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
8. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
9. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement.
Jacob R; Hanlon AL; Horwitz EM; Movsas B; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):695-701. PubMed ID: 15708247
[TBL] [Abstract][Full Text] [Related]
10. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
11. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
[TBL] [Abstract][Full Text] [Related]
12. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
Liauw SL; Stadler WM; Correa D; Weichselbaum RR; Jani AB
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):125-30. PubMed ID: 19695789
[TBL] [Abstract][Full Text] [Related]
14. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?
Zapatero A; García-Vicente F; Martín de Vidales C; Cruz Conde A; Ibáñez Y; Fernández I; Rabadán M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1279-85. PubMed ID: 20932659
[TBL] [Abstract][Full Text] [Related]
15. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
[TBL] [Abstract][Full Text] [Related]
16. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
Burri RJ; Ho AY; Forsythe K; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1315-21. PubMed ID: 20044216
[TBL] [Abstract][Full Text] [Related]
17. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
[TBL] [Abstract][Full Text] [Related]
18. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?
Khuntia D; Reddy CA; Mahadevan A; Klein EA; Kupelian PA
Cancer; 2004 Mar; 100(6):1283-92. PubMed ID: 15022298
[TBL] [Abstract][Full Text] [Related]
19. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
[TBL] [Abstract][Full Text] [Related]
20. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]